Sunday, June 14, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 286 of 1,261

  1. US 11236100

    Modulators of eukaryotic initiation factor 2B, compositions and methods

    DENALI THERAPEUTICS INC. · Granted Feb 1, 2022 · Expires Jan 27, 2042

    granted

  2. US 11236080

    Protein kinase inhibitors

    Princeton Drug Discovery, Inc · Granted Feb 1, 2022 · Expires Jan 27, 2042

    granted

  3. US 11236099

    Heterocyclic compound

    Takeda Pharmaceutical Company Limited · Granted Feb 1, 2022 · Expires Jan 27, 2042

    granted

  4. US 11236035

    Salts of treprostinil

    United Therapeutics Corporation · Granted Feb 1, 2022 · Expires Jan 27, 2042

    granted

  5. AR 119975

    MÉTODOS PARA RADIOMARCAR ANTAGONISTAS DE GRPR Y SUS KITS

    ADVANCED ACCELERATOR APPLICATIONS ITALY SRL [IT] · Granted Jan 26, 2022 · Expires Jan 21, 2042

    granted

  6. AR 120033

    ANTAGONISTA RADIOMARCADO DE GRPR PARA USO COMO AGENTE TERAGNÓSTICO

    ADVANCED ACCELERATOR APPLICATIONS ITALY SRL [IT] · Granted Jan 26, 2022 · Expires Jan 21, 2042

    granted

  7. US 11230542

    Inhibitors of integrated stress response pathway

    PRAXIS BIOTECH LLC · Granted Jan 25, 2022 · Expires Jan 20, 2042

    granted

  8. LT 3544598

    CANNABINOIDS FOR PROPHYLACTIC TREATMENT OF INVOLUNTARY WEIGHT LOSS

    AOP ORPHAN PHARMACEUTICALS GMBH [AT] · Granted Jan 25, 2022 · Expires Jan 20, 2042

    granted

  9. US 11230530

    Human plasma kallikrein inhibitors

    BioCryst Pharmaceuticals, Inc. · Granted Jan 25, 2022 · Expires Jan 20, 2042

    granted

  10. US 11230607

    CD47 targeted therapies for the treatment of infectious disease

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Jan 25, 2022 · Expires Jan 20, 2042

    granted

  11. US 11230587

    Ligands of B7H receptor in the treatment of osteopenia and osteoporosis

    UNIVERSITÀ DEGLI STUDI DEL PIEMONTE ORIENTALE “AMEDEO AVOGADRO” · Granted Jan 25, 2022 · Expires Jan 20, 2042

    granted

  12. US 11230535

    CFTR regulators and methods of use thereof

    The Regents of the University of California · Granted Jan 25, 2022 · Expires Jan 20, 2042

    granted

  13. US 11230541

    Heterocyclic compound

    Takeda Pharmaceutical Company Limited · Granted Jan 25, 2022 · Expires Jan 20, 2042

    granted

  14. US 11229681

    Dominant-negative FGF2 antagonists

    The Regents of the University of California · Granted Jan 25, 2022 · Expires Jan 20, 2042

    granted

  15. US 11229606

    Extended release compositions comprising pyridostigmine

    Amneal Complex Products Research LLC · Granted Jan 25, 2022 · Expires Jan 20, 2042

    granted

  16. US 11230592

    DNA antibody constructs for use against middle east respiratory syndrome coronavirus

    Inovio Pharmaceuticals, Inc. · Granted Jan 25, 2022 · Expires Jan 20, 2042

    granted

  17. US 11230590

    Hyperimmunized egg product for treatment of necrotic enteritis in poultry

    United States of America as represented by the Secretary of the Air Force · Granted Jan 25, 2022 · Expires Jan 20, 2042

    granted

  18. US 11230591

    CMV neutralizing antigen binding proteins

    The Board of Regents of the University of Texas System · Granted Jan 25, 2022 · Expires Jan 20, 2042

    granted

  19. US 11230568

    Melanocortin 1 receptor ligands and methods of use

    Arizona Board of Regents on Behalf of the University of Arizona · Granted Jan 25, 2022 · Expires Jan 20, 2042

    granted

  20. US 11230569

    Antiplasmodial compounds

    The Board of Regents of the University of Oklahoma · Granted Jan 25, 2022 · Expires Jan 20, 2042

    granted

  21. US 11230565

    Synthesis of backbone modified morpholino oligonucleotides and chimeras using phosphoramidite chemistry

    The Regents of the University of Colorado · Granted Jan 25, 2022 · Expires Jan 20, 2042

    granted

  22. US 11230549

    Quinolino-pyrrolidin-2-one derivative and application thereof

    Medshine Discovery Inc. · Granted Jan 25, 2022 · Expires Jan 20, 2042

    granted

  23. US 11230544

    Substituted 1,3,4-thiadiazoles as GLS1 inhibitors

    Medshine Discovery Inc. · Granted Jan 25, 2022 · Expires Jan 20, 2042

    granted

  24. US 11230554

    Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds

    Rigel Pharmaceuticals, Inc. · Granted Jan 25, 2022 · Expires Jan 20, 2042

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.